These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 20588278)
1. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Lassen U; Molife LR; Sorensen M; Engelholm SA; Vidal L; Sinha R; Penson RT; Buhl-Jensen P; Crowley E; Tjornelund J; Knoblauch P; de Bono JS Br J Cancer; 2010 Jun; 103(1):12-7. PubMed ID: 20588278 [TBL] [Abstract][Full Text] [Related]
2. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial. Hainsworth JD; Daugaard G; Lesimple T; Hübner G; Greco FA; Stahl MJ; Büschenfelde CM; Allouache D; Penel N; Knoblauch P; Fizazi KS Cancer; 2015 May; 121(10):1654-61. PubMed ID: 25611313 [TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Ramalingam SS; Parise RA; Ramanathan RK; Lagattuta TF; Musguire LA; Stoller RG; Potter DM; Argiris AE; Zwiebel JA; Egorin MJ; Belani CP Clin Cancer Res; 2007 Jun; 13(12):3605-10. PubMed ID: 17510206 [TBL] [Abstract][Full Text] [Related]
4. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Rasmussen A; Ooi CE; Buhl-Jensen P; Brown R; Evans TR; DeBono JS Clin Cancer Res; 2008 Feb; 14(3):804-10. PubMed ID: 18245542 [TBL] [Abstract][Full Text] [Related]
5. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial. Luu T; Frankel P; Beumer JH; Lim D; Cristea M; Appleman LJ; Lenz HJ; Gandara DR; Kiesel BF; Piekarz RL; Newman EM Cancer Chemother Pharmacol; 2019 Dec; 84(6):1201-1208. PubMed ID: 31522242 [TBL] [Abstract][Full Text] [Related]
6. A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours. van Herpen CM; Eskens FA; de Jonge M; Desar I; Hooftman L; Bone EA; Timmer-Bonte JN; Verweij J Br J Cancer; 2010 Oct; 103(9):1362-8. PubMed ID: 20877350 [TBL] [Abstract][Full Text] [Related]
7. Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. Dizon DS; Damstrup L; Finkler NJ; Lassen U; Celano P; Glasspool R; Crowley E; Lichenstein HS; Knoblach P; Penson RT Int J Gynecol Cancer; 2012 Jul; 22(6):979-86. PubMed ID: 22694911 [TBL] [Abstract][Full Text] [Related]
8. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. Takebe N; Beumer JH; Kummar S; Kiesel BF; Dowlati A; O'Sullivan Coyne G; Piekarz R; Rubinstein L; Fogli LK; Vaishampayan U; Goel S; O'Bryant CL; El-Rayes BF; Chung V; Lenz HJ; Kim R; Belani CP; Tuscano JM; Schelman W; Moore N; Doroshow JH; Chen AP Br J Clin Pharmacol; 2019 Nov; 85(11):2499-2511. PubMed ID: 31271459 [TBL] [Abstract][Full Text] [Related]
9. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Pauer LR; Olivares J; Cunningham C; Williams A; Grove W; Kraker A; Olson S; Nemunaitis J Cancer Invest; 2004; 22(6):886-96. PubMed ID: 15641487 [TBL] [Abstract][Full Text] [Related]
10. A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Agarwal N; McPherson JP; Bailey H; Gupta S; Werner TL; Reddy G; Bhat G; Bailey EB; Sharma S Cancer Chemother Pharmacol; 2016 Feb; 77(2):299-308. PubMed ID: 26719074 [TBL] [Abstract][Full Text] [Related]
11. A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors. Jones SF; Infante JR; Thompson DS; Mohyuddin A; Bendell JC; Yardley DA; Burris HA Cancer Chemother Pharmacol; 2012 Sep; 70(3):471-5. PubMed ID: 22851205 [TBL] [Abstract][Full Text] [Related]
12. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Dizon DS; Blessing JA; Penson RT; Drake RD; Walker JL; Johnston CM; Disilvestro PA; Fader AN Gynecol Oncol; 2012 May; 125(2):367-71. PubMed ID: 22366594 [TBL] [Abstract][Full Text] [Related]
13. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Mackay HJ; Hirte H; Colgan T; Covens A; MacAlpine K; Grenci P; Wang L; Mason J; Pham PA; Tsao MS; Pan J; Zwiebel J; Oza AM Eur J Cancer; 2010 Jun; 46(9):1573-9. PubMed ID: 20304628 [TBL] [Abstract][Full Text] [Related]
14. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers. Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616 [TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954 [TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207 [TBL] [Abstract][Full Text] [Related]
17. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. Leiser AL; Maluf FC; Chi DS; Sabbatini P; Hensley ML; Schwartz L; Venkatraman E; Spriggs D; Aghajanian C Int J Gynecol Cancer; 2007; 17(2):379-86. PubMed ID: 17362316 [TBL] [Abstract][Full Text] [Related]
18. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. Yeo W; Chung HC; Chan SL; Wang LZ; Lim R; Picus J; Boyer M; Mo FK; Koh J; Rha SY; Hui EP; Jeung HC; Roh JK; Yu SC; To KF; Tao Q; Ma BB; Chan AW; Tong JH; Erlichman C; Chan AT; Goh BC J Clin Oncol; 2012 Sep; 30(27):3361-7. PubMed ID: 22915658 [TBL] [Abstract][Full Text] [Related]
19. Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors. Wheler J; Mutch D; Lager J; Castell C; Liu L; Jiang J; Traynor AM Oncologist; 2017 Apr; 22(4):377-e37. PubMed ID: 28275119 [TBL] [Abstract][Full Text] [Related]
20. Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. Goey AK; Sissung TM; Peer CJ; Trepel JB; Lee MJ; Tomita Y; Ehrlich S; Bryla C; Balasubramaniam S; Piekarz R; Steinberg SM; Bates SE; Figg WD J Clin Pharmacol; 2016 Apr; 56(4):461-73. PubMed ID: 26313268 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]